Next Article in Journal / Special Issue
Reduced Pro-Inflammatory Cytokines after Eight Weeks of Low-Dose Naltrexone for Fibromyalgia
Previous Article in Journal
Glycosylated Triterpenoids as Endosomal Escape Enhancers in Targeted Tumor Therapies

Modulation of NMDA Receptor Activity in Fibromyalgia

Departments of Medicine, Monash University and Rheumatology, MonashHealth, Melbourne 3168, Australia
Author to whom correspondence should be addressed.
Academic Editor: Kim Lawson
Biomedicines 2017, 5(2), 15;
Received: 23 February 2017 / Revised: 1 April 2017 / Accepted: 7 April 2017 / Published: 11 April 2017
(This article belongs to the Special Issue Drug Therapies for the Treatment of Fibromyalgia)
Activation of the N-methyl-d-aspartate receptor (NMDAR) results in increased sensitivity of spinal cord and brain pathways that process sensory information, particularly those which relate to pain. The NMDAR shows increased activity in fibromyalgia and hence modulation of the NMDAR is a target for therapeutic intervention. A literature review of interventions impacting on the NMDAR shows a number of drugs to be active on the NMDAR mechanism in fibromyalgia patients, with variable clinical effects. Low-dose intravenous ketamine and oral memantine both show clinically useful benefit in fibromyalgia. However, consideration of side-effects, logistics and cost need to be factored into management decisions regarding use of these drugs in this clinical setting. Overall benefits with current NMDAR antagonists appear modest and there is a need for better strategy trials to clarify optimal dose schedules and to delineate potential longer–term adverse events. Further investigation of the role of the NMDAR in fibromyalgia and the effect of other molecules that modulate this receptor appear important to enhance treatment targets in fibromyalgia. View Full-Text
Keywords: fibromyalgia; drugs; NMDA receptor; ketamine; memantine fibromyalgia; drugs; NMDA receptor; ketamine; memantine
Show Figures

Figure 1

MDPI and ACS Style

Littlejohn, G.; Guymer, E. Modulation of NMDA Receptor Activity in Fibromyalgia. Biomedicines 2017, 5, 15.

AMA Style

Littlejohn G, Guymer E. Modulation of NMDA Receptor Activity in Fibromyalgia. Biomedicines. 2017; 5(2):15.

Chicago/Turabian Style

Littlejohn, Geoffrey, and Emma Guymer. 2017. "Modulation of NMDA Receptor Activity in Fibromyalgia" Biomedicines 5, no. 2: 15.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop